{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:40:44Z","timestamp":1776904844031,"version":"3.51.2"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"IconOVir"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>ICVB-1042 is an oncolytic adenovirus containing modifications to enhance replication, lysis, and viral spreading in tumor cells. The anti-tumor activity, immune activation, tropism, selectivity, and mechanism of action were evaluated in preparation for a first-in-human study. ICVB-1042 was at least 100-fold more cytotoxic in A549 cells than in normal primary cells tested, demonstrating its high tumor selectivity and a low likelihood of targeting primary tissues. ICVB-1042 administered to mice intravenously or intratumorally was effective in reducing tumor burden. Its intravenous administration also inhibited tumor growth in orthotopic models. ICVB-1042 was well tolerated in mice compared to HAdV-C5 (Wt Ad5), with reduced liver sequestration, supporting safety of the drug for systemic delivery. These preclinical data demonstrating the safety and potency of ICVB-1042 for treatment of various solid tumors support the ongoing clinical investigation (NCT05904236).<\/jats:p>","DOI":"10.1038\/s42003-024-06839-6","type":"journal-article","created":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T11:02:27Z","timestamp":1726225347000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Nonclinical characterization of ICVB-1042 as a selective oncolytic adenovirus for solid tumor treatment"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4743-1775","authenticated-orcid":false,"given":"Yu","family":"Kato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathaniel","family":"Rice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Pokrass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinkil","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruben","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica J.","family":"Field","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6554-1446","authenticated-orcid":false,"given":"Heba","family":"Nowyhed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,13]]},"reference":[{"key":"6839_CR1","doi-asserted-by":"publisher","first-page":"4676","DOI":"10.1182\/blood.V88.12.4676.bloodjournal88124676","volume":"88","author":"MJ Cantwell","year":"1996","unstructured":"Cantwell, M. J., Sharma, S., Friedmann, T. & Kipps, T. J. Adenovirus vector infection of chronic lymphocytic leukemia B cells. Blood 88, 4676\u20134683 (1996).","journal-title":"Blood"},{"key":"6839_CR2","doi-asserted-by":"publisher","first-page":"13159","DOI":"10.1073\/pnas.95.22.13159","volume":"95","author":"RP Leon","year":"1998","unstructured":"Leon, R. P. et al. Adenoviral-mediated gene transfer in lymphocytes. Proc. Natl Acad. Sci. USA 95, 13159\u201313164 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"6839_CR3","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13045-020-00922-1","volume":"13","author":"O Hemminki","year":"2020","unstructured":"Hemminki, O., Dos Santos, J. M. & Hemminki, A. Oncolytic viruses for cancer immunotherapy. J. Hematol. Oncol. 13, 84 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"6839_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.omto.2020.03.003","volume":"17","author":"V Cervera-Carrascon","year":"2020","unstructured":"Cervera-Carrascon, V. et al. Comparison of clinically relevant oncolytic virus platforms for enhancing T cell therapy of solid tumors. Mol. Ther. Oncolytics 17, 47\u201360 (2020).","journal-title":"Mol. Ther. Oncolytics"},{"key":"6839_CR5","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1128\/JVI.72.3.2224-2232.1998","volume":"72","author":"X Xiao","year":"1998","unstructured":"Xiao, X., Li, J. & Samulski, R. J. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J. Virol. 72, 2224\u20132232 (1998).","journal-title":"J. Virol."},{"key":"6839_CR6","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/s41434-021-00278-2","volume":"29","author":"Z Wang","year":"2022","unstructured":"Wang, Z. et al. Characterization of integration frequency and insertion sites of adenovirus DNA into mouse liver genomic DNA following intravenous injection. Gene Ther. 29, 322\u2013332 (2022).","journal-title":"Gene Ther."},{"key":"6839_CR7","doi-asserted-by":"publisher","first-page":"S164","DOI":"10.1002\/jgm.496","volume":"6","author":"C Volpers","year":"2004","unstructured":"Volpers, C. & Kochanek, S. Adenoviral vectors for gene transfer and therapy. J. Gene Med. 6, S164\u2013S171 (2004).","journal-title":"J. Gene Med."},{"key":"6839_CR8","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/nbt1066","volume":"23","author":"AW Nguyen","year":"2005","unstructured":"Nguyen, A. W. & Daugherty, P. S. Evolutionary optimization of fluorescent proteins for intracellular FRET. Nat. Biotechnol. 23, 355\u2013360 (2005).","journal-title":"Nat. Biotechnol."},{"key":"6839_CR9","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1038\/bjc.2013.509","volume":"109","author":"M Reeh","year":"2013","unstructured":"Reeh, M. et al. Presence of the Coxsackievirus and Adenovirus Receptor (CAR) in human neoplasms: a multitumour array analysis. Br. J. Cancer 109, 1848\u20131858 (2013).","journal-title":"Br. J. Cancer"},{"key":"6839_CR10","first-page":"2953","volume":"61","author":"TP Cripe","year":"2001","unstructured":"Cripe, T. P. et al. Fiber knob modifications overcome low, heterogeneous expression of the coxsackievirus-adenovirus receptor that limits adenovirus gene transfer and oncolysis for human rhabdomyosarcoma cells. Cancer Res. 61, 2953\u20132960 (2001).","journal-title":"Cancer Res."},{"key":"6839_CR11","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1093\/jnci\/95.9.652","volume":"95","author":"J Fueyo","year":"2003","unstructured":"Fueyo, J. et al. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J. Natl Cancer Inst. 95, 652\u2013660 (2003).","journal-title":"J. Natl Cancer Inst."},{"key":"6839_CR12","doi-asserted-by":"publisher","first-page":"6416","DOI":"10.1128\/JVI.00445-09","volume":"83","author":"L Coughlan","year":"2009","unstructured":"Coughlan, L. et al. In vivo retargeting of adenovirus type 5 to \u03b1v\u03b26 integrin results in reduced hepatotoxicity and improved tumor uptake following systemic delivery. J. Virol. 83, 6416\u20136428 (2009).","journal-title":"J. Virol."},{"key":"6839_CR13","doi-asserted-by":"publisher","first-page":"863850","DOI":"10.3389\/fcell.2022.863850","volume":"10","author":"C Bergonzini","year":"2022","unstructured":"Bergonzini, C., Kroese, K., Zweemer, A. J. M. & Danen, E. H. J. Targeting integrins for cancer therapy - disappointments and opportunities. Front. Cell Dev. Biol. 10, 863850 (2022).","journal-title":"Front. Cell Dev. Biol."},{"key":"6839_CR14","doi-asserted-by":"publisher","first-page":"14429","DOI":"10.1128\/JVI.79.22.14429-14436.2005","volume":"79","author":"M Marttila","year":"2005","unstructured":"Marttila, M. et al. CD46 is a cellular receptor for all species B adenoviruses except types 3 and 7. J. Virol. 79, 14429\u201314436 (2005).","journal-title":"J. Virol."},{"key":"6839_CR15","doi-asserted-by":"publisher","first-page":"7478","DOI":"10.1128\/JVI.79.12.7478-7491.2005","volume":"79","author":"DM Shayakhmetov","year":"2005","unstructured":"Shayakhmetov, D. M., Gaggar, A., Ni, S., Li, Z.-Y. & Lieber, A. Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J. Virol. 79, 7478\u20137491 (2005).","journal-title":"J. Virol."},{"key":"6839_CR16","doi-asserted-by":"publisher","first-page":"5483","DOI":"10.1073\/pnas.0711757105","volume":"105","author":"O Kalyuzhniy","year":"2008","unstructured":"Kalyuzhniy, O. et al. Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc. Natl Acad. Sci. USA 105, 5483\u20135488 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"6839_CR17","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/nm.3107","volume":"19","author":"Z Xu","year":"2013","unstructured":"Xu, Z. et al. Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement. Nat. Med. 19, 452\u2013457 (2013).","journal-title":"Nat. Med."},{"key":"6839_CR18","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1158\/1535-7163.MCT-10-0332","volume":"9","author":"JJ Short","year":"2010","unstructured":"Short, J. J. et al. Substitution of adenovirus serotype 3 hexon onto a serotype 5 oncolytic adenovirus reduces factor X binding, decreases liver tropism, and improves antitumor efficacy. Mol. Cancer Ther. 9, 2536\u20132544 (2010).","journal-title":"Mol. Cancer Ther."},{"key":"6839_CR19","doi-asserted-by":"publisher","first-page":"S864","DOI":"10.1016\/j.annonc.2021.08.1416","volume":"32","author":"I-M Svane","year":"2021","unstructured":"Svane, I.-M. et al. 1032TiP a phase I, first-in-human, study of TILT-123, a tumor-selective oncolytic adenovirus encoding TNFa and IL-2, in participants with advanced melanoma receiving adoptive T-cell therapy with tumor-infiltrating lymphocytes. Ann. Oncol. 32, S864 (2021).","journal-title":"Ann. Oncol."},{"key":"6839_CR20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40425-016-0121-5","volume":"4","author":"T Ranki","year":"2016","unstructured":"Ranki, T. et al. Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers. J. Immunother. Cancer 4, 17 (2016).","journal-title":"J. Immunother. Cancer"},{"key":"6839_CR21","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40425-019-0510-7","volume":"7","author":"J-P Machiels","year":"2019","unstructured":"Machiels, J.-P. et al. A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE). J. Immunother. Cancer 7, 20 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"6839_CR22","doi-asserted-by":"publisher","first-page":"5819","DOI":"10.1128\/JVI.74.13.5819-5824.2000","volume":"74","author":"RJ O\u2019Connor","year":"2000","unstructured":"O\u2019Connor, R. J. & Hearing, P. The E4-6\/7 protein functionally compensates for the loss of E1A expression in adenovirus infection. J. Virol. 74, 5819\u20135824 (2000).","journal-title":"J. Virol."},{"key":"6839_CR23","doi-asserted-by":"publisher","first-page":"3643","DOI":"10.1128\/jvi.63.9.3643-3650.1989","volume":"63","author":"R Reichel","year":"1989","unstructured":"Reichel, R. et al. The adenovirus E4 gene, in addition to the E1A gene, is important for trans-activation of E2 transcription and for E2F activation. J. Virol. 63, 3643\u20133650 (1989).","journal-title":"J. Virol."},{"key":"6839_CR24","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1101\/gad.3.11.1699","volume":"3","author":"MM Huang","year":"1989","unstructured":"Huang, M. M. & Hearing, P. The adenovirus early region 4 open reading frame 6\/7 protein regulates the DNA binding activity of the cellular transcription factor, E2F, through a direct complex. Genes Dev. 3, 1699\u20131710 (1989).","journal-title":"Genes Dev."},{"key":"6839_CR25","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1038\/80474","volume":"6","author":"C Heise","year":"2000","unstructured":"Heise, C. et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat. Med. 6, 1134\u20131139 (2000).","journal-title":"Nat. Med."},{"key":"6839_CR26","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1006\/viro.2002.1772","volume":"305","author":"K Doronin","year":"2003","unstructured":"Doronin, K. et al. Overexpression of the ADP (E3-11.6K) protein increases cell lysis and spread of adenovirus. Virology 305, 378\u2013387 (2003).","journal-title":"Virology"},{"key":"6839_CR27","doi-asserted-by":"publisher","first-page":"E4884","DOI":"10.1073\/pnas.1312420110","volume":"110","author":"M Windheim","year":"2013","unstructured":"Windheim, M. et al. A unique secreted adenovirus E3 protein binds to the leukocyte common antigen CD45 and modulates leukocyte functions. Proc. Natl Acad. Sci. USA 110, E4884\u2013E4893 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"6839_CR28","doi-asserted-by":"publisher","first-page":"5515","DOI":"10.1128\/JVI.76.11.5515-5521.2002","volume":"76","author":"JM Friedman","year":"2002","unstructured":"Friedman, J. M. & Horwitz, M. S. Inhibition of tumor necrosis factor alpha-induced NF-\u03baB activation by the adenovirus E3-10.4\/14.5K complex. J. Virol. 76, 5515\u20135521 (2002).","journal-title":"J. Virol."},{"key":"6839_CR29","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/cgt.2009.12","volume":"16","author":"S Bortolanza","year":"2009","unstructured":"Bortolanza, S. et al. Deletion of the E3-6.7K\/gp19K region reduces the persistence of wild-type adenovirus in a permissive tumor model in Syrian hamsters. Cancer Gene Ther. 16, 703\u2013712 (2009).","journal-title":"Cancer Gene Ther."},{"key":"6839_CR30","doi-asserted-by":"publisher","first-page":"3270","DOI":"10.1074\/jbc.M008218200","volume":"276","author":"CA Benedict","year":"2001","unstructured":"Benedict, C. A. et al. Three adenovirus E3 proteins cooperate to evade apoptosis by tumor necrosis factor-related apoptosis-inducing ligand receptor-1 and -2. J. Biol. Chem. 276, 3270\u20133278 (2001).","journal-title":"J. Biol. Chem."},{"key":"6839_CR31","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1073\/pnas.94.6.2587","volume":"94","author":"Y Ilan","year":"1997","unstructured":"Ilan, Y. et al. Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression. Proc. Natl Acad. Sci. USA 94, 2587\u20132592 (1997).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"6839_CR32","doi-asserted-by":"publisher","first-page":"5289","DOI":"10.1128\/jvi.67.9.5289-5298.1993","volume":"67","author":"TW Hermiston","year":"1993","unstructured":"Hermiston, T. W., Tripp, R. A., Sparer, T., Gooding, L. R. & Wold, W. S. Deletion mutation analysis of the adenovirus type 2 E3-gp19K protein: identification of sequences within the endoplasmic reticulum lumenal domain that are required for class I antigen binding and protection from adenovirus-specific cytotoxic T lymphocytes. J. Virol. 67, 5289\u20135298 (1993).","journal-title":"J. Virol."},{"key":"6839_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2236-3","volume":"11","author":"J Ma","year":"2020","unstructured":"Ma, J. et al. Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer. Cell Death Dis. 11, 48 (2020).","journal-title":"Cell Death Dis."},{"key":"6839_CR34","doi-asserted-by":"publisher","first-page":"12785","DOI":"10.1128\/JVI.01732-07","volume":"81","author":"W Hongjie","year":"2007","unstructured":"Hongjie, W. et al. Identification of CD46 binding sites within the adenovirus serotype 35 fiber knob. J. Virol. 81, 12785\u201312792 (2007).","journal-title":"J. Virol."},{"key":"6839_CR35","doi-asserted-by":"publisher","first-page":"12785","DOI":"10.1128\/JVI.01732-07","volume":"81","author":"H Wang","year":"2007","unstructured":"Wang, H. et al. Identification of CD46 binding sites within the adenovirus serotype 35 fiber knob. J. Virol. 81, 12785\u201312792 (2007).","journal-title":"J. Virol."},{"key":"6839_CR36","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/nm952","volume":"9","author":"A Gaggar","year":"2003","unstructured":"Gaggar, A., Shayakhmetov, D. M. & Lieber, A. CD46 is a cellular receptor for group B adenoviruses. Nat. Med. 9, 1408\u20131412 (2003).","journal-title":"Nat. Med."},{"key":"6839_CR37","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.3390\/v15071424","volume":"15","author":"H Aitkenhead","year":"2023","unstructured":"Aitkenhead, H., Stuart, D. I. & El Omari, K. Structure of bovine CD46 ectodomain. Viruses 15, 1424 (2023).","journal-title":"Viruses"},{"key":"6839_CR38","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1128\/JVI.80.8.3912-3922.2006","volume":"80","author":"T Krey","year":"2006","unstructured":"Krey, T. et al. Function of bovine CD46 as a cellular receptor for bovine viral diarrhea virus is determined by complement control protein 1. J. Virol. 80, 3912\u20133922 (2006).","journal-title":"J. Virol."},{"key":"6839_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/antib9040059","volume":"9","author":"M Elvington","year":"2020","unstructured":"Elvington, M., Liszewski, M. K. & Atkinson, J. P. CD46 and oncologic interactions: Friendly fire against cancer. Antibodies 9, 1\u201314 (2020).","journal-title":"Antibodies"},{"key":"6839_CR40","doi-asserted-by":"crossref","unstructured":"Uchio, E. M. et al. A phase 3, single-arm study of CG0070 in subjects with nonmuscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG). J. Clin. Oncol. 40, 6-Suppl, TPS598 (2022).","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS598"},{"key":"6839_CR41","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1200\/JCO.2017.35.15_suppl.2002","volume":"35","author":"FF Lang","year":"2017","unstructured":"Lang, F. F. et al. Phase 1b open-label randomized study of the oncolytic adenovirus DNX-2401 administered with or without interferon gamma for recurrent glioblastoma. J. Clin. Oncol. 35, 2002\u20132002 (2017).","journal-title":"J. Clin. Oncol."},{"key":"6839_CR42","doi-asserted-by":"crossref","unstructured":"Garcia-Carbonero, R. et al. Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection. J. Immunother. Cancer 5, 71 (2017).","DOI":"10.1186\/s40425-017-0277-7"},{"key":"6839_CR43","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.cell.2016.05.077","volume":"166","author":"SD Cappell","year":"2016","unstructured":"Cappell, S. D., Chung, M., Jaimovich, A., Spencer, S. L. & Meyer, T. Irreversible APCCdh1 inactivation underlies the point of no return for cell-cycle entry. Cell 166, 167\u2013180 (2016).","journal-title":"Cell"},{"key":"6839_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-5-1","volume":"5","author":"TG Graves","year":"2006","unstructured":"Graves, T. G., Harr, M. W., Crawford, E. L. & Willey, J. C. Stable low-level expression of p21WAF1\/CIP1 in A549 human bronchogenic carcinoma cell line-derived clones down-regulates E2F1 mRNA and restores cell proliferation control. Mol. Cancer 5, 1 (2006).","journal-title":"Mol. Cancer"},{"key":"6839_CR45","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41591-020-01182-9","volume":"27","author":"R Sender","year":"2021","unstructured":"Sender, R. & Milo, R. The distribution of cellular turnover in the human body. Nat. Med. 27, 45\u201348 (2021).","journal-title":"Nat. Med."},{"key":"6839_CR46","doi-asserted-by":"crossref","unstructured":"Reid, T., Warren, R. & Kirn, D. Intravascular adenoviral agents in cancer patients: Lessons from clinical trials. Cancer Gene Ther. 9, 979\u2013986 (2002).","DOI":"10.1038\/sj.cgt.7700539"},{"key":"6839_CR47","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/imr.12382","volume":"269","author":"TL Mcgaha","year":"2016","unstructured":"Mcgaha, T. L. & Karlsson, M. C. I. Apoptotic cell responses in the splenic marginal zone: A paradigm for immunologic reactions to apoptotic antigens with implications for autoimmunity. Immunol. Rev. 269, 26\u201343 (2016).","journal-title":"Immunol. Rev."},{"key":"6839_CR48","doi-asserted-by":"publisher","first-page":"6193","DOI":"10.4049\/jimmunol.169.11.6193","volume":"169","author":"LM Sedger","year":"2002","unstructured":"Sedger, L. M. et al. Bone marrow B cell apoptosis during in vivo influenza virus infection requires TNF-\u03b1 and lymphotoxin-\u03b1. J. Immunol. 169, 6193\u20136201 (2002).","journal-title":"J. Immunol."},{"key":"6839_CR49","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3389\/fimmu.2014.00353","volume":"5","author":"NC Di Paolo","year":"2014","unstructured":"Di Paolo, N. C. Recognition of human oncogenic viruses by host pattern-recognition receptors. Front. Immunol. 5, 353 (2014).","journal-title":"Front. Immunol."},{"key":"6839_CR50","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1016\/j.juro.2012.07.097","volume":"188","author":"JM Burke","year":"2012","unstructured":"Burke, J. M. et al. A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. J. Urol. 188, 2391\u20132397 (2012).","journal-title":"J. Urol."},{"key":"6839_CR51","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2222\/jsv.58.11","volume":"58","author":"T Fujiwara","year":"2008","unstructured":"Fujiwara, T. & Tanaka, N. Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter. Uirusu 58, 11\u201318 (2008).","journal-title":"Uirusu"},{"key":"6839_CR52","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1089\/hum.2007.002","volume":"18","author":"IV Ulasov","year":"2007","unstructured":"Ulasov, I. V. et al. Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma. Hum. Gene Ther. 18, 589\u2013602 (2007).","journal-title":"Hum. Gene Ther."},{"key":"6839_CR53","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1159\/000448430","volume":"105","author":"D Yu","year":"2017","unstructured":"Yu, D. et al. Preclinical evaluation of AdVince, an oncolytic adenovirus adapted for treatment of liver metastases from neuroendocrine cancer. Neuroendocrinology 105, 54\u201366 (2017).","journal-title":"Neuroendocrinology"},{"key":"6839_CR54","first-page":"1148","volume":"81","author":"Q Liu","year":"2021","unstructured":"Liu, Q. et al. Abstract 1148: SynOV1.1: a synthetic gene circuit controlled oncolytic adenovirus demonstrating high tumor specificity, potent antitumor efficacy and high synergy with an anti-PD-L1 monoclonal antibody in preclinical hepatocellular carcinoma models. Cancer Res. 81, 1148\u20131148 (2021).","journal-title":"Cancer Res."},{"key":"6839_CR55","doi-asserted-by":"publisher","first-page":"eaat9321","DOI":"10.1126\/scitranslmed.aat9321","volume":"11","author":"G Pascual-Pasto","year":"2019","unstructured":"Pascual-Pasto, G. et al. Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01. Sci. Transl. Med. 11, eaat9321 (2019).","journal-title":"Sci. Transl. Med."},{"key":"6839_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells10020246","volume":"10","author":"R Havunen","year":"2021","unstructured":"Havunen, R. et al. Cytokine-coding oncolytic adenovirus TILT-123 is safe, selective, and effective as a single agent and in combination with immune checkpoint inhibitor anti-PD-1. Cells 10, 1\u201316 (2021).","journal-title":"Cells"},{"key":"6839_CR57","doi-asserted-by":"publisher","first-page":"4701","DOI":"10.3390\/cancers14194701","volume":"14","author":"B Oronsky","year":"2022","unstructured":"Oronsky, B. et al. Oncolytic adenoviruses: the cold war against cancer finally turns hot. Cancers 14, 4701 (2022).","journal-title":"Cancers"},{"key":"6839_CR58","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1038\/sj.mt.6300239","volume":"15","author":"M Cascallo","year":"2007","unstructured":"Cascallo, M. et al. Systemic toxicity-efficacy profile of ICOVIR-5, a potent and selective oncolytic adenovirus based on the pRB pathway. Mol. Ther. 15, 1607\u20131615 (2007).","journal-title":"Mol. Ther."},{"key":"6839_CR59","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1593\/neo.81674","volume":"11","author":"M Huch","year":"2009","unstructured":"Huch, M. et al. Urokinase-type plasminogen activator receptor transcriptionally controlled adenoviruses eradicate pancreatic tumors and liver metastasis in mouse models. Neoplasia 11, 518\u2013528, 4 p following 528 (2009).","journal-title":"Neoplasia"},{"key":"6839_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14715\/cmb\/2017.63.7.1","volume":"63","author":"BM Abbas","year":"2017","unstructured":"Abbas, B. M., El-Mogy, M. A. & Haj-Ahmad, Y. Oncolytic E1B 55KDa-deleted adenovirus replication is independent of p53 levels in cancer cells. Cell. Mol. Biol. 63, 1\u201311 (2017).","journal-title":"Cell. Mol. Biol."},{"key":"6839_CR61","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/1097-0215(20001101)88:3<454::AID-IJC19>3.0.CO;2-T","volume":"88","author":"H Lee","year":"2000","unstructured":"Lee, H. et al. Oncolytic potential of E1B 55 kDa-deleted YKL-1 recombinant adenovirus: correlation with p53 functional status. Int. J. Cancer 88, 454\u2013463 (2000).","journal-title":"Int. J. Cancer"},{"key":"6839_CR62","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1101\/gad.190678.112","volume":"26","author":"WA Freed-Pastor","year":"2012","unstructured":"Freed-Pastor, W. A. & Prives, C. Mutant p53: one name, many proteins. Genes Dev. 26, 1268\u20131286 (2012).","journal-title":"Genes Dev."},{"key":"6839_CR63","doi-asserted-by":"publisher","first-page":"e2409","DOI":"10.1371\/journal.pone.0002409","volume":"3","author":"I Kuhn","year":"2008","unstructured":"Kuhn, I. et al. Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. PLoS ONE 3, e2409 (2008).","journal-title":"PLoS ONE"},{"key":"6839_CR64","doi-asserted-by":"publisher","first-page":"S84","DOI":"10.1016\/S1525-0016(16)44427-8","volume":"15","author":"TW Hermiston","year":"2007","unstructured":"Hermiston, T. W. et al. Directed evolution generates a novel potent and selective Ad3\/Ad11p chimeric oncolytic virus for the treatment of colon cancer. Mol. Ther. 15, S84 (2007).","journal-title":"Mol. Ther."},{"key":"6839_CR65","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1074\/jbc.M409934200","volume":"280","author":"LS Hart","year":"2005","unstructured":"Hart, L. S. et al. The adenovirus E4orf6 protein inhibits DNA double strand break repair and radiosensitizes human tumor cells in an E1B-55K-independent manner. J. Biol. Chem. 280, 1474\u20131481 (2005).","journal-title":"J. Biol. Chem."},{"key":"6839_CR66","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/gt.2016.32","volume":"23","author":"MR Duffy","year":"2016","unstructured":"Duffy, M. R., Doszpoly, A., Turner, G., Nicklin, S. A. & Baker, A. H. The relevance of coagulation factor X protection of adenoviruses in human sera. Gene Ther. 23, 592\u2013596 (2016).","journal-title":"Gene Ther."},{"key":"6839_CR67","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1089\/hum.2018.107","volume":"30","author":"M Garc\u00eda","year":"2019","unstructured":"Garc\u00eda, M. et al. A Phase 1 trial of oncolytic adenovirus ICOVIR-5 administered intravenously to cutaneous and uveal melanoma patients. Hum. Gene Ther. 30, 352\u2013364 (2019).","journal-title":"Hum. Gene Ther."},{"key":"6839_CR68","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1089\/hum.1998.9.13-1885","volume":"9","author":"KS Harrod","year":"1998","unstructured":"Harrod, K. S., Hermiston, T. W., Trapnell, B. C., Wold, W. S. M. & Whitsett, J. A. Lung-specific expression of adenovirus E3-14.7K in transgenic mice attenuates adenoviral vector-mediated lung inflammation and enhances transgene expression. Hum. Gene Ther. 9, 1885\u20131898 (1998).","journal-title":"Hum. Gene Ther."},{"key":"6839_CR69","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.omto.2020.11.006","volume":"20","author":"KN Barton","year":"2020","unstructured":"Barton, K. N. et al. Phase I trial of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for the treatment of metastatic pancreatic cancer. Mol. Ther. Oncolytics 20, 94\u2013104 (2020).","journal-title":"Mol. Ther. Oncolytics"}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-024-06839-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-024-06839-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-024-06839-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T12:19:50Z","timestamp":1726229990000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-024-06839-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,13]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["6839"],"URL":"https:\/\/doi.org\/10.1038\/s42003-024-06839-6","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,13]]},"assertion":[{"value":"8 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: All authors are employees or consultants of IconOVir Bio and may own stock or stock options.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1132"}}